Saluda Medical

We welcome Mike Mathias to Saluda Medical as Chief Commercial Officer! Mr. Mathias is an accomplished executive leader with a proven track record of commercial execution in high growth businesses. Through the creation of customer and employee-centric strategies, he has built commercial organizations from infancy to sustainable and successful franchises. We are excited Mike is joining our mission to transform patients' lives with revolutionary neural-sensing technology.

Today, the American Society of Pain and Neuroscience ASPN released their latest episode of the Pain Unfiltered Podcast titled, “Are All Closed Loops Created Equal?” Thank you to Drs. Tim Deer, MD, Patrick Buchanan, M.D., Jason E. Pope, MD, DABPM, FIPP, and Johnathan Goree for the in-depth discussion! #KnowTheDose #ControlTheDose #BiomarkerBasedDosing #ClosedLoop #ECAPs 

Our European Smart Faculty Group met in Amsterdam last week to discuss biomarker-based dosing in SCS, and to learn about our next-generation product launch which will take place in the coming months across Europe. Thank you to our faculty for your support and collaboration, and a special thank you to Dr. Johnathan Goree for joining us from the US to share his real-world experience of using neural dosing in his practice. Harold Nijhuis Jan Willem Kallewaard @Frank Huygen Johan Van de Minkelis Serge Nikolic Simon Thomson Prof. Dr. Jarek Maciaczyk Tony Van Havenbergh Karel Hanssens Johnathan Goree Clair Jackson Tim Palmer Jeff Colella Dave Mugan Sander van Geel Dr. Catharina Zielinski Peter Shepherd Rene Kraaiveld Celine Neutens Katharina Hermanski

Authors concluded “…it is imperative that we as a field reshape how we evaluate SCS. Similar to recently published RCTs in the space, expectations for pain relief should include objective improvements in quality of life measures.” To read the Tim Deer, MD et. al., Letter to the Editor in Pain Medicine, visit: https://lnkd.in/gdq435tp #KnowtheDose #ControltheDose #BiomarkerbasedDosing #Closedloop To read about the science and evidence behind SmartLoop® technology including holistic response beyond pain scores, visit: https://lnkd.in/eDFCwzfw

Join the October International Neuromodulation Society Journal Club Webinar this Thursday, October 17th to learn more about the use of biomarkers for optimization of spinal cord stimulation. Register here for free: https://lnkd.in/eHVNrAH

Join us at the American Society of Pain and Neuroscience ASPN Collaborative Pain Summit this weekend in Nashville, TN to learn more about the science and evidence of SmartLoop® technology. Jason E. Pope, MD, DABPM, FIPP Patrick Buchanan, M.D. Johnathan Goree Erika Petersen Chau M. Vu, M.D. Patrick McGinn, PA-C To learn more about SmartLoop® technology exclusively from Saluda Medical, visit: https://lnkd.in/gX6abP8Z #KnowtheDose #ControltheDose #BiomarkerbasedDosing Risks and Important Safety Info https://lnkd.in/d2XZ_Asn Rx Only The Saluda Medical Evoke® SCS System is indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs.

Recently, we spent an exciting Saturday morning in New Orleans at the Ochsner Pain Symposium. At the symposium, we were joined by an Evoke® System patient, Heather, to share with clinicians a live demonstration of SmartLoop® dose-control technology and the ability to leverage biomarkers to drive objective therapy optimization. Thank you to Dr. yashar Eshraghi and Hazem Eissa at Ochsner Health, and Maged Guirguis, Chairman of Pain Med Services, for sharing your expertise. Thank you to Mena N. Mekhail, D.O. and  Leah Muller, MD PhD for your help creating this experience from science to treatment. To learn more about SmartLoop® technology exclusively from Saluda Medical, visit: https://lnkd.in/gX6abP8Z #KnowtheDose #ControltheDose #BiomarkerbasedDosing Risks and Important Safety Info https://lnkd.in/d2XZ_Asn Rx Only The Saluda Medical Evoke® SCS System is indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs.

Nurses from around Europe met in London to learn more about using biomarker-based dosing to objectively optimize therapy leading to a new level of predictability and durability of outcomes. Thank you to our European Nurse partners for your engagement and passion to ensure the best possible outcomes for your SCS patients. Caro Edelbroek @Karen Sanderson Pieter Van Looy Ralph Aarsman Wilma Vissink Colette Schulz Merry Macdonald Jenny Jennings #KnowtheDose #ControltheDose #BiomarkerbasedDosing Learn more about the Evoke® System, visit: https://lnkd.in/gX6abP8Z Risks and Important Safety Info https://lnkd.in/d2XZ_Asn  Rx Only  The Saluda Medical Evoke® SCS System is indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs.

Congratulations to Dr. Jason E. Pope, MD, DABPM, FIPP for earning Top 3 abstract at the Pacific Spine and Pain Society (PSPS) 5th Annual Conference last weekend! Dr. Pope detailed how objective, biomarker-based dosing drives maximum pain relief in SCS. Objective, Not Subjective. To read the full publication on using objective neural metrics to drive maximum analgesic effect, visit: https://lnkd.in/ei_jZJ7w To learn more about SmartLoop® technology exclusively from Saluda Medical, visit: https://lnkd.in/gX6abP8Z   #KnowtheDose #ControltheDose #BiomarkerbasedDosing Risks and Important Safety Info https://lnkd.in/d2XZ_Asn Rx Only The Saluda Medical Evoke® SCS System is indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs.

The Trial phase of SCS have traditionally relied solely on patient feedback and if the device was on over the trial period to evaluate success or not. SmartLoop® Dose-Control Technology changes that. Last week, Dr. Dustin Reynolds, MD at OrthoNeuro in Ohio completed a trial with a patient who presented with low back and buttock pain. After two days, the patient reported only around 30% pain relief despite using the device continuously. Upon looking at the objective neural metrics, it was observed the neural dose was 1.2, meaning it was 20% above ECAP threshold which is below the published value of 1.4 that has shown to drive max pain relief. The patient’s neural dose was increased to 1.4 based on published data resulting in an increase in pain relief to 80% and the patient becoming a profound responder. Objective, Not Subjective. To read more about how to use neural metrics to drive max analgesic effect, visit our website at: https://lnkd.in/ei_jZJ7w To learn more about SmartLoop® technology exclusively from Saluda Medical, visit: https://lnkd.in/gX6abP8Z    #KnowtheDose #ControltheDose #Biomarkerbaseddosing Individual results may vary Risks and Important Safety Info https://lnkd.in/d2XZ_Asn Rx Only The Saluda Medical Evoke® SCS System is indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs.